@文章{Verhamme606，作者= {Verhamme, Katia M.C.和Afonso, Ana和Romio, Silvana和Stricker, Bruno C.和Brusselle, Guy G.O.和Sturkenboom, Miriam C.J.M.}，标题= {tiotropium Respimat软雾吸入器与HandiHaler的使用与COPD患者的死亡率}，volume = {42}， number = {3}， page ={606—615}，year = {2013}， doi ={10.1183/09031936.00005813}，出版商={欧洲呼吸学会}，摘要= {tiotropium，一种长效抗胆碱能药物，188bet官网地址通过handdihaler或Respimat传递。随机对照试验表明，使用噻托溴铵Respimat会增加死亡风险。我们比较了tiotropium Respimat与HandiHaler之间的死亡风险。在综合初级保健信息数据库中，我们定义了一个患者源人群，年龄>=40岁，>=1年的随访。基于处方数据，我们定义了噻托溴铵使用(Respimat或HandiHaler)的发作。使用Cox比例风险回归分析计算这些发作内的死亡风险。在源人群中，有1287例患者提供了24522次噻托溴铵使用。496名患者在接触HandiHaler或Respimat时死亡。使用Respimat与死亡风险增加近30%相关(调整后HR 1.27, 95% CI 1.03{\textendash}1.57)，其中心脑血管死亡风险最高(调整后HR 1.56, 95% CI 1.08{\textendash}2.25)。 The risk was higher in patients with co-existing cardiovascular disease (adjusted HR 1.36, 95\% CI 1.07{\textendash}1.73) than in patients without (adjusted HR 1.02, 95\% CI 0.61{\textendash}1.71). Use of tiotropium Respimat was associated with an almost 30\% increase of mortality compared with HandiHaler and the association was the strongest for cardiovascular/cerebrovascular death. It is unclear whether this association is causal or due to residual confounding by chronic obstructive pulmonary disease severity. Tiotropium Respimat was associated with a 30\% increase in mortality compared with HandiHaler in COPD http://ow.ly/mpmhp}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/42/3/606}, eprint = {//www.qdcxjkg.com/content/42/3/606.full.pdf}, journal = {European Respiratory Journal} }